Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Alpine SPA-Bungalow made with lightweight wooden modules

The SPA-Bungalow offers visitors an unique sauna experience at an altitude of 2,690 metres, with spectacular alpine views. The bungalow at the Loetschenpass Hut hotel in Switzerland combines a sauna, a relaxation area with a bed, and a bathroom with a shower. The SPA-Bungalow’s three wooden modules are made entirely from Kerto® LVL (laminated veneer lumber), making them lightweight enough to be transported via helicopter. Kerto® LVL proved to be the ideal fast, light and green material for this exclusive design.The designer behind the SPA-Bungalow concept is the Swiss designer and wellness

Bricknode Broker 2.15 release: White labels and updated tables

Earlier this week Bricknode released a new version of its benchmark-setting, cloudbased financial software Bricknode Broker. The new release contains a few upgrades compared to earlier versions. Most noteworthy is the new White Label Manager.Since Bricknode Broker saw the day of light back in 2015, it has served it's customers well, making the handling of securities relatively easy. But it isn't until now that Bricknode's customers can offer the same services to _their_ clients.Version 2.15 of Bricknode Broker fixes this. White Label Manager is an add-on that allows clients of

Interim report 2018-01-01 – 2018-06-30

The Board and Chief Executive Officer of Cereno Scientific AB herewith present the interim report for the second quarter 2018.Summary of the interim report Six months (2018-01-01 – 2018-06-30) · Net sales were 0 SEK (0 SEK). · Loss after financial items was -4 908 504 SEK (- 1 857 958). · Loss per share was -0,45 SEK (-0,17 SEK) before dilution and -0,42 SEK (-0,16 SEK) after dilution. · Equity ratio was 59,2 % (91,9 %). Three months (2018-04-01 – 2018-06-30) · Net sales were 0 SEK (0 SEK). · Loss after financial items was -3 103 061 SEK (-1 118 555 SEK). ·

Christer Simrén is appointed as new Chairman of the Board in ChromoGenics

Christer Simrén is appointed as new Chairman of the Board in ChromoGenics AB (publ) starting from today, 30 August 2018.Anders Brännström, the Chairman of the Board, has after eight years in the Board of Directors decided to step down as Chairman of the Board and hand over to Christer Simrén, today a member of the Board. Anders Brännström will remain as a member of the Board for a transitional period.Chairman of the Board Anders Brännström says; "I am pleased to be able to hand over to Christer Simrén. ChromoGenics is in an exciting phase with the recent acquisition of I-Window, which

Fondia continues its growth, internationalisation and profitability

Fondia Half Year Financial Report January-June 2018 January to June 2018 in brief (comparison period January to June 2017 results in brackets, unless noted otherwise, Jansson&Norin reported as a part of Fondia as from 1.2.2018) · Net sales increased by 21.0% to €10.70 million (8.84). The acquisition in Sweden is estimated to equal to approximately 8 percent of the increase in the net sales. · Operating profit (EBIT) increased by 41.2% to €1.62 million (1.15). Operating margin was 15.1% (13.0). · Comparable operating

Gaming Innovation Group launches GiG Comply and signs with Mr Green as first client

Gaming Innovation Group Inc. (GiG) has signed an agreement with Mr Green, one of the brands of MRG Group (MRG), for the provision of its newly launched, innovative B2B marketing compliance technology, GiG Comply. This monitoring service is designed in response to operators’ needs to further strengthen control over third party advertising and brand protection. GiG Comply drives responsible gaming by providing improved visibility of where and how brands are being advertised. The service helps protect them from promotion on websites which are not brand-safe. It also protects from misleading

REALFICTION HOLDING AB (publ) OFFENTLIGÖR DELÅRSRAPPORT FÖR JANUARI – JUNI 2018.

Realfiction Holding AB (”Realfiction”) offentliggör härmed delårsrapporten för perioden januari –juni 2018. Delårsrapporten i sin helhet bifogas som ett separat dokument och kan även laddas ner från bolaget webbplats (www.realfiction.com). Tryckt exemplar kan beställas via investor@realfiction.com. Nedan följer en kort sammanfattning.ANDRA KVARTALET (1 april – 30 juni 2018)   •          Koncernens nettoomsättning uppgick till 6 259 KSEK. •          Resultatet före skatt uppgick till - 3 968 KSEK. •          Resultatet per aktie* uppgick till - 0,29 SEK. •          Kassaflöde

IRLAB reports promising efficacy data from Phase IIa-study with IRL752

The overall results of the recently completed Phase IIa study indicate that IRL752 – a candidate drug developed for the treatment of Parkinson’s disease dementia – improves symptoms associated with executive functions and dementia in Parkinson's disease. Effects on balance and fall tendency – so called axial symptoms – and apathy, were significant in patients treated with IRL752 but not in patients treated with placebo. Further, the study indicated a positive trend in results from cognitive tests, despite the short duration of the study. These symptoms currently lack satisfactory treatment.

Mr Green strengthen player traffic control with Comply

Award-winning iGaming operator Mr Green strengthen their control over affiliate player traffic through the new compliance software Comply.As part of their strong focus on player protection, Mr Green has signed an agreement with Gaming Innovation Group to use their new compliance software Comply. The software scans websites featuring client brands and searches for events and conditions set by the client to make sure the correct information is presented to readers as well as making sure the message only reaches the approved audience. Jesper Kärrbrink, CEO Mr Green Ltd commented: “We

REALFICTION HOLDING AB (publ) ANNOUNCES HALF-YEAR INTERIM REPORT FOR JANUARY - JUNE 2018

The company announces that the Half-Year Interim Report for January - June 2018 is now available. The full report is attached as a separate document and can also be downloaded from the company’s website (www.realfiction.com. A printed copy can be ordered via investor@realfiction.com. Below is a brief summary of the Half-Year Interim Report.Q2 2018 (1 April – 30 June 2018)  •          Revenue totaled TSEK 6,259 •          Profit/(loss) after financial income and expenses amounted to TSEK -3,968 •          Earnings per share* SEK –0.29 •          Cash flow from operating

Another metro win for KONE in China with deal to equip Wuxi Metro line 3

KONE Corporation, press release, August 30, 2018 KONE, a global leader in the elevator and escalator industry, has won an order to equip line 3 of the Wuxi Metro in the southern part of China's Jiangsu Province. The deal builds on KONE's previous contribution to line 2 of the Wuxi Metro.  Line 3 of the Wuxi Metro runs 28.5 kilometers in a southeastern direction, starting at the Su Temple in the northwest, and ending at the Shuo Fang International Airport in the south. All 21 stations along the line are situated underground. KONE will supply the metro line with 99 KONE

Fixed income investor meetings

Odfjell SE will hold a number of fixed income investor meetings during the following days. Following such meetings, a NOK denominated senior unsecured bond issue may follow, subject to inter alia market conditions.A potential bond issue would be intended for general corporate purposes, including refinancing of ODF06, maturing in December 2018.Clarksons Platou Securities AS, Pareto Securities AS and Swedbank Norge will arrange the meetings.For further information, please contact:Bjørn Kristian Røed, Manager Investor Relations & ResearchTel: +47 55 27 47 33E-mail: bkr@odfjell.com

Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm

On August 28 Asarina Pharma applied to be listed on Nasdaq First North, generating significant interest. On Tuesday, September 4 the company presents to investors at Aktiekvällen in Gothenburg, followed by further events in Stockholm."We’re developing the world's first dedicated treatment for PMDD, the severest form of PMS," says Peter Nordkild, CEO of Asarina Pharma. “PMDD is a painful condition that impacts 1-in-20 women of a fertile age worldwide—as well as their families, friends and co-workers. I look forward to presenting our clinical data, and the major market potential for investors,

Poitras Foundry orders SinterCast Ladle Tracker® technology

· Ladle Tracker installation for grey and ductile iron automotive foundry · Improved process control, quality assurance, productivity and traceability · First stand-alone installation of SinterCast Ladle Tracker® technology[L’islet, Quebec and Stockholm, 30 August 2018] – Poitras Foundry, a grey and ductile iron automotive component foundry located in Quebec, Canada, has become the first foundry to order the stand-alone ladle tracking technology developed by the Swedish process control specialist SinterCast. The technology is based on the placement of radio frequency identification (

EC approves Bydureon BCise device for T2 diabetes

30 August 2018 07:00 BST European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes AstraZeneca today announced that the European Commission (EC) has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorisation for Bydureon (exenatide extended release) for the treatment of patients with type-2 diabetes. The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled pen device that requires no titration and is

Interim report January–June 2018 BEWiSynbra Group AB (publ), corp. reg. no. 556972-1128

COMMENTS BY CEO  On May 14, we announced the completion of the acquisition of Synbra Holding B.V.  The current half-year report thus marks the first time we are reporting the consolidated results for the new Group. Under our new name, BEWiSynbra Group, we are now forming Europe’s leading player for EPS products. Integrating the two companies without disruptions for our customers has been a prime consideration from the start, and it is with great satisfaction that we can report that our progress to date is in line with our ambitions. If we take our raw material production units as

Danish Air Transport becomes Norra’s majority shareholder

Danish Air Transport (DAT) acquires 60 % of Nordic Regional Airlines AB (Norra) from Finnair, which held the 100 % stake in Norra on an interim basis after Norra’s previous owners who held 60 % of shares exited the business in November 2017. Finnair continues to own 40 % of the company. As such, the transaction has no impact on Norra’s operations, personnel or purchase agreement between Finnair and Norra. Norra operates Finnair’s domestic and European routes with a total of 24 ATR and Embraer aircraft. “Finnair’s and Norra’s partnership model in domestic and regional purchase traffic

PAXMAN publishes its interim report for the period 1 April to 30 June 2018

Continued expansion in line with business planThe Group’s sales amounted to 23.6 (14.0) MSEK as of 30 June, of which 12.6 (7.1) MSEK in the second quarter of the year. Net profit/loss totalled -2.5 (0.7) MSEK as of 30 June, of which -0.9 (-0.4) MSEK refer to the period April – June. Earnings per share were -0.16 (0.09) SEK for the first six months of the year, of which -0.05 (-0.03) SEK refer to Q2.  Cash flow before financing activities was -10.4 (-5.7) MSEK for the first six months of the year, of which -3.6 (-3.2) MSEK for the second quarter. Total assets amounted to 45.4 (50.0)

Carl-Johan Dalsgaard Appointed New CEO of Vicore Pharma

The board of directors of Vicore Pharma Holding AB (”Vicore”) has on August 29, 2018 appointed Dr. Carl-Johan Dalsgaard as new CEO of Vicore. Carl-Johan Dalsgaard is CEO of INIM Pharma AB which was recently acquired by Vicore. He is a trained physician and PhD from the Karolinska Institute and has over 25 years of experience from drug development with Astra/AstraZeneca and several biotech companies.Carl-Johan Dalsgaard replaces Per Jansson who has been the CEO of Vicore Pharma Holding AB since 2013 and also the CEO of Vicore Pharma AB since 2007. The appointment was made in light of Vicore’

Herantis Pharma Oyj: Manager's Transactions - Antti Vuolanto

Herantis Pharma Oyj: Manager's Transactions - Antti Vuolanto Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Vuolanto, Antti Position: Other senior manager Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114244_3 ____________________________________________ Transaction date: 2018-08-29 Venue not applicable

Herantis Pharma Oyj: Manager's Transactions - Pekka Mattila

Herantis Pharma Oyj: Manager's Transactions - Pekka Mattila Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Mattila, Pekka Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828115121_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Herantis Pharma Oyj: Manager's Transactions - Aki Prihti

Herantis Pharma Oyj: Manager's Transactions - Aki Prihti Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Prihti, Aki Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114149_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Herantis Pharma Oyj: Manager's Transactions - Timo Veromaa

Herantis Pharma Oyj: Manager's Transactions - Timo Veromaa Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Veromaa, Timo Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114448_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

Herantis Pharma Oyj: Manager's Transactions - Frans Wuite

Herantis Pharma Oyj: Manager's Transactions - Frans Wuite Herantis Pharma PlcCompany release 30 Aug 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Wuite, Frans Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20180828114648_2 ____________________________________________ Transaction date: 2018-08-29 Venue not

There are no items matching the current filter
There are no more items matching the current filter
Back to top